ATE417607T1 - Sphingolipide gegen krankhafte prozesse in lipid rafts - Google Patents

Sphingolipide gegen krankhafte prozesse in lipid rafts

Info

Publication number
ATE417607T1
ATE417607T1 AT05756574T AT05756574T ATE417607T1 AT E417607 T1 ATE417607 T1 AT E417607T1 AT 05756574 T AT05756574 T AT 05756574T AT 05756574 T AT05756574 T AT 05756574T AT E417607 T1 ATE417607 T1 AT E417607T1
Authority
AT
Austria
Prior art keywords
sphingolipids
lipid rafts
against illegal
illegal processes
processes
Prior art date
Application number
AT05756574T
Other languages
English (en)
Inventor
Tobias Braxmeier
Tim Friedrichson
Wolfgang Froehner
Gary Jennings
Georg Schlechtingen
Cornelia Schroeder
Hans-Joachim Knoelker
Kai Simons
Marino Zerial
Teymuras Kurzchalia
Original Assignee
Jado Technologies Gmbh
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jado Technologies Gmbh, Max Planck Gesellschaft filed Critical Jado Technologies Gmbh
Application granted granted Critical
Publication of ATE417607T1 publication Critical patent/ATE417607T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
AT05756574T 2004-06-29 2005-06-29 Sphingolipide gegen krankhafte prozesse in lipid rafts ATE417607T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015248 2004-06-29
US63647104P 2004-12-16 2004-12-16

Publications (1)

Publication Number Publication Date
ATE417607T1 true ATE417607T1 (de) 2009-01-15

Family

ID=35134634

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05756574T ATE417607T1 (de) 2004-06-29 2005-06-29 Sphingolipide gegen krankhafte prozesse in lipid rafts

Country Status (9)

Country Link
US (1) US7629385B2 (de)
EP (2) EP1763342B1 (de)
JP (1) JP2008504330A (de)
AT (1) ATE417607T1 (de)
AU (1) AU2005259501A1 (de)
CA (1) CA2572310A1 (de)
DE (1) DE602005011802D1 (de)
ES (1) ES2317259T3 (de)
WO (1) WO2006002909A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
EP1618876A1 (de) * 2004-07-19 2006-01-25 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Verwendung von Sphingolipiden zur Vorbeugung und Behandlung von Atherosklerose
GB0513431D0 (en) * 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
WO2008111916A1 (en) * 2007-03-09 2008-09-18 Agency For Science, Technology And Research Glycosphingolipid-aided intracellular delivery of cargo molecules
DE102008002409A1 (de) * 2008-06-13 2009-12-17 Evonik Goldschmidt Gmbh Enzymatische Synthese von Sphingolipiden
DE102008002410A1 (de) * 2008-06-13 2009-12-17 Evonik Goldschmidt Gmbh Enzymatische Synthese von Sphingolipiden
US8853452B2 (en) * 2009-02-10 2014-10-07 The Administrators Of The Tulane Educational Fund Compounds, their syntheses, compositions, and methods to treat cancer
US20120301457A1 (en) * 2010-01-22 2012-11-29 Surachai Supattapone LIPID COFACTORS FOR FACILITATING PROPOGATION OF PRPsc
US20130266977A1 (en) * 2010-02-16 2013-10-10 President And Fellows Of Harvard College Methods and systems for detection of microbes
US20130203715A1 (en) 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
JP5877204B2 (ja) 2010-09-29 2016-03-02 パルマトリックス，インコーポレイテッド 吸入用の一価金属カチオン乾燥粉末
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
JP2013071918A (ja) * 2011-09-28 2013-04-22 Shiseido Co Ltd フィラグリン産生促進剤
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US20140316154A1 (en) * 2013-03-15 2014-10-23 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
JP6232008B2 (ja) 2015-03-19 2017-11-15 国立大学法人北海道大学 酸化抑制剤及びこれを用いた油脂含有飲食品
JP6661192B2 (ja) * 2016-01-19 2020-03-11 国立大学法人北海道大学 Ｓｍｓ２阻害活性を有するセラミド誘導体
EP3259990A1 (de) * 2016-06-20 2017-12-27 Ceva Sante Animale Verfahren zur bekämpfung von ektoparasiten bei nichtmenschlichen säugern
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
CN120037152A (zh) * 2022-11-01 2025-05-27 深圳市迪克曼生物科技有限公司 亚麻酸衍生的神经酰胺的应用
WO2026017703A2 (en) * 2024-07-16 2026-01-22 Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern Multifunctional sphingomyelin and ceramide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5411094A (en) 1992-11-12 1994-06-08 Carnegie Institution Of Washington Ceramide derivatives
JPH08113535A (ja) 1994-10-13 1996-05-07 Sumitomo Pharmaceut Co Ltd 神経細胞の変性または死滅抑制剤
GB9614889D0 (en) 1996-07-16 1996-09-04 John P Robarts Research Inst T Ceramide promoters of haematopoiesis
US6610835B1 (en) * 1998-02-12 2003-08-26 Emory University Sphingolipid derivatives and their methods of use
DE19841794A1 (de) * 1998-09-12 2000-03-16 Beiersdorf Ag Kombinationen von Antiadhäsiva (Ceramide und Sphingosine und Derivate) und Mikrobiziden
US7820718B1 (en) 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
DE19946737A1 (de) 1999-09-29 2001-04-19 Max Planck Gesellschaft Verwendung von Gangliosiden zur Modulation von Sphingolipid-Cholesterin-Mikrodomänen
AU6273401A (en) 2000-06-14 2001-12-24 Sankyo Co Ceramide kinase and dna encoding the same
US20040004522A1 (en) 2002-07-03 2004-01-08 Sweeney Anthony C. N-way signal divider
GB0301395D0 (en) * 2003-01-21 2003-02-19 Univ Aston Inflammatory disorder treatment

Also Published As

Publication number Publication date
EP1763342A2 (de) 2007-03-21
AU2005259501A1 (en) 2006-01-12
US7629385B2 (en) 2009-12-08
US20080090913A1 (en) 2008-04-17
JP2008504330A (ja) 2008-02-14
EP2065040A3 (de) 2009-09-09
EP1763342B1 (de) 2008-12-17
WO2006002909A2 (en) 2006-01-12
EP2065040A2 (de) 2009-06-03
WO2006002909A3 (en) 2007-03-22
CA2572310A1 (en) 2006-01-12
ES2317259T3 (es) 2009-04-16
DE602005011802D1 (de) 2009-01-29

Similar Documents

Publication Publication Date Title
ATE417607T1 (de) Sphingolipide gegen krankhafte prozesse in lipid rafts
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
NO20082768L (no) Levodopa prodroge mesylat, sammensetninger og anvendelser derav
WO2008005534A3 (en) Orally dissolving formulations of memantine
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
WO2007075598A3 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
CL2003002683A1 (es) Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos,
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
EP2305640A3 (de) Substituierte Diphenyl-Ether, -Amine, -Sulfide und -Methane zur Behandlung von Beschwerden der Atemwege
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
MX2013007319A (es) Compuestos y su uso como inhibidores de sitio beta de escision de enzima (bace).
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2008000981A1 (es) Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
UA84048C2 (ru) Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties